Jan Tuzil (Jan Tužil)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 14

Top Venues

Expert review of gastroenterology & hepatology

Expert review of cardiovascular therapy

Expert review of pharmacoeconomics & outcomes research

The patient

Value Outcomes

Charles University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Value Outcomes

Czechia

Project and Research Specialist

PharmInvent

Czechia

Junior PV Specialist :: Signal Management

BioRad

France

Junior Researche Specialist :: SysDig

Academy of Science

Czechia

Researcher :: Institute of Organic Chemistry and Biochemistry

Education History

Charles University

Czechia

PHD :: 1st Medicine faculty

Charles University Prague

Czechia

MSC :: Natural Sciences/Biochemistry

Publications

Jan Tuzil, Jan Matějka, Mamas Andreas Mamas, Tomáš Doležal
Short-term risk of periprocedural stroke relative to radial vs. femoral access: systematic review, meta-analysis, study sequential analysis and meta-regression of 2,188,047 real-world cardiac catheterizations. Expert review of cardiovascular therapy (2023)
Jan Tuzil, Jan Matějka, Mamas Andreas Mamas, Tomáš Doležal
Short-term risk of periprocedural stroke relative to radial vs. femoral access: systematic review, meta-analysis, study sequential analysis and meta-regression of 2,188,047 real-world cardiac catheterizations. Expert review of cardiovascular therapy (2023)
Jan Tuzil, Jan Matějka, Mamas Andreas Mamas, Tomáš Doležal
Short-term risk of periprocedural stroke relative to radial vs. femoral access: systematic review, meta-analysis, study sequential analysis and meta-regression of 2,188,047 real-world cardiac catheterizations. Expert review of cardiovascular therapy (2023)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova, Tomas Dolezal
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert review of gastroenterology & hepatology 17 (1) (2022)
Daniela Štrosová, Jan Tuzil, Barbora Velacková Turková, Barbora Filková Pilnáčková, Lada Lžičařová de Souza, Helena Doležalová, Michaela Rašková, Michal Dufek, Tomáš Doležal
Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide. Pharmaceuticals (Basel, Switzerland) 15 (10) (2022)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova, Tomas Dolezal
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert review of gastroenterology & hepatology (2022)
Barbora Turková, Jan Tuzil, Barbora Pilnáčková, Helena Doležalová, Daniela Štrosová, Vít Petrů, Ester Seberová, Tomáš Doležal
Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic. Immunotherapy 14 (14) (2022)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova, Tomas Dolezal
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert review of gastroenterology & hepatology 17 (1) (2022)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova, Tomas Dolezal
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert review of gastroenterology & hepatology (2022)
Eva Ornstová, Jan Tuzil, Kateřina Chadimová, Tomas Mlcoch, Tomáš Doležal
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension. Expert review of pharmacoeconomics & outcomes research 22 (8) (2022)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova, Tomas Dolezal
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert review of gastroenterology & hepatology (2022)
Jan Tuzil, Jana Bartakova, Torquil Watt, Tomas Dolezal
Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies. Expert review of pharmacoeconomics & outcomes research 21 (6) (2021)
Jan Tuzil, Tomas Mlcoch, Jitka Jirčíková, Jakub Závada, Lucie Nekvindová, Michal Svoboda, Michal Uher, Zlatuše Křístková, Jiri Vencovsky, Karel Pavelka, Tomáš Doležal
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Expert opinion on biological therapy 20 (2) (2019)
Tomas Mlcoch, Jan Tuzil, Liliana Sedova, Jiri Stolfa, Monika Urbanova, David Suchy, Andrea Smrzova, Jitka Jircikova, Tereza Hrnciarova, Karel Pavelka, Tomas Dolezal
Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. The patient 11 (3) (2018)

Jan Tuzil.css-eqlu8i{font-size:small;padding-left:4px;} (Jan Tužil)

Publication Activity (10 Years)

Top Topics

Top Venues

Jan Tuzil (Jan Tužil)